DE60336341D1 - Zusammensetzungen und verfahren zur förderung des neuronalen wachstums - Google Patents

Zusammensetzungen und verfahren zur förderung des neuronalen wachstums

Info

Publication number
DE60336341D1
DE60336341D1 DE60336341T DE60336341T DE60336341D1 DE 60336341 D1 DE60336341 D1 DE 60336341D1 DE 60336341 T DE60336341 T DE 60336341T DE 60336341 T DE60336341 T DE 60336341T DE 60336341 D1 DE60336341 D1 DE 60336341D1
Authority
DE
Germany
Prior art keywords
compositions
methods
neuronal growth
promoting neuronal
chondroitinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60336341T
Other languages
English (en)
Inventor
Elliott A Gruskin
J F Iaci
A M Vecchione
S J Hogan
G Roy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Application granted granted Critical
Publication of DE60336341D1 publication Critical patent/DE60336341D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02005—Chondroitin AC lyase (4.2.2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02019—Chondroitin B lyase (4.2.2.19)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60336341T 2002-05-04 2003-05-05 Zusammensetzungen und verfahren zur förderung des neuronalen wachstums Expired - Lifetime DE60336341D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37766902P 2002-05-04 2002-05-04
PCT/US2003/014156 WO2004108069A2 (en) 2002-05-04 2003-05-05 Compositions and methods for promoting neuronal outgrowth

Publications (1)

Publication Number Publication Date
DE60336341D1 true DE60336341D1 (de) 2011-04-21

Family

ID=33510266

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60336341T Expired - Lifetime DE60336341D1 (de) 2002-05-04 2003-05-05 Zusammensetzungen und verfahren zur förderung des neuronalen wachstums

Country Status (7)

Country Link
US (4) US8183350B2 (de)
EP (2) EP2301564A1 (de)
AT (1) ATE500842T1 (de)
AU (1) AU2003304173A1 (de)
DE (1) DE60336341D1 (de)
ES (1) ES2362648T3 (de)
WO (1) WO2004108069A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183350B2 (en) 2002-05-04 2012-05-22 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
AU2003265561A1 (en) * 2002-08-15 2004-03-03 Acorda Therapeutics, Inc. Chimeric protein
US7959914B2 (en) * 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
EP2460881B1 (de) 2003-05-16 2017-05-03 Acorda Therapeutics, Inc. Proteoglycan-abbauende Mutanten zur Behandlung des ZNS
EP1631234B1 (de) * 2003-05-16 2011-09-14 Acorda Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von zns-schäden
MXPA06013345A (es) 2004-05-18 2008-10-31 Acorda Therapeutics Inc Metodos para purificar condrointinasa y sus formulaciones estables.
WO2007038548A2 (en) 2005-09-26 2007-04-05 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
WO2008045970A2 (en) 2006-10-10 2008-04-17 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
US8198083B1 (en) 2007-10-31 2012-06-12 William Gunter Loudon Organotypic slices of the central nervous system
EP2153844A1 (de) * 2008-08-14 2010-02-17 HAUBECK, Hans-Dieter Humane Hyaluronidasen zum erneuten axonalen Wachstum
WO2012136768A1 (en) 2011-04-08 2012-10-11 Hans-Dieter Haubeck Use of mutants of human hyaluronidase ph-20 with increased chondroitinase activity for axonal regrowth
CN111593040B (zh) * 2020-06-20 2022-08-30 山东大学 硫酸皮肤素裂解酶及其应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270194A (en) 1989-08-31 1993-12-14 Instrumentation Laboratory Spa Stabilized glucose oxidase from Aspergillus Niger
EP0493533A4 (en) 1989-10-27 1992-10-28 Case Western Reserve University Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5679650A (en) 1993-11-24 1997-10-21 Fukunaga; Atsuo F. Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JP3980657B2 (ja) 1992-06-26 2007-09-26 生化学工業株式会社 コンドロイチナーゼａｂｃ、その製造法及び医薬組成物
US5496718A (en) 1992-06-26 1996-03-05 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Chondroitinase ABC isolated from proteus vulgaris ATCC 6896
US7008783B1 (en) 1992-09-22 2006-03-07 Maruha Corporation Gene encoding chondroitinase ABC and uses therefor
WO1994025567A1 (en) 1993-04-23 1994-11-10 American Cyanamid Company CLONING AND EXPRESSION OF THE CHONDROITINASE I AND II GENES FROM $i(P. VULGARIS)
US5578480A (en) 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
AU1176595A (en) 1993-11-12 1995-05-29 International Technology Management Associates, Ltd. Methods of repairing connective tissues
US5498536A (en) 1994-04-22 1996-03-12 American Cyanamid Company Chondroitinase II from Proteus vulgaris
DE69528128T2 (de) 1994-06-10 2003-03-13 United States Surgical Corp., Norwalk Rekombinante Chimäre Proteine und Verfahren zur deren Verwendung
US6093563A (en) 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US5997863A (en) * 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
US6326166B1 (en) 1995-12-29 2001-12-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
US6254870B1 (en) 1995-02-03 2001-07-03 G. D. Searle & Co. Thrombopoietin: IL-3 fusion protein
US5792743A (en) 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
US6313265B1 (en) 1995-07-24 2001-11-06 The Scripps Research Institute Neurite outgrowth-promoting polypeptides containing fibronectin type III repeats and methods of use
US5869301A (en) 1995-11-02 1999-02-09 Lockhead Martin Energy Research Corporation Method for the production of dicarboxylic acids
JP3702450B2 (ja) 1996-12-18 2005-10-05 ニプロ株式会社 乳酸脱水素酵素測定用試薬
US5969301A (en) * 1996-12-23 1999-10-19 Cullum, Jr.; Burton E. Acoustic diffuser panel system and method
WO1998046258A2 (en) 1997-04-11 1998-10-22 Beth Israel Deaconess Medical Center, Inc. Use of chondroitinase in the manufacture of a medicament in the treatment and prevention of mucoid secretions
JP4172842B2 (ja) 1997-05-02 2008-10-29 生化学工業株式会社 コンドロイチナーゼ組成物
EP0875253B1 (de) 1997-05-02 2005-04-06 Seikagaku Corporation Chondroitinase enthaltende Zusammensetzungen
DK0900569T3 (da) * 1997-08-22 2003-01-27 Seikagaku Kogyo Co Ltd Terapeutisk middel til behandling af herniaramt intervertebral diskus
US20010006630A1 (en) 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
US6153187A (en) 1997-09-02 2000-11-28 Insight Strategy & Marketing Ltd. Use of glycosaminoglycans degrading enzymes for management of airway associated diseases
PT1887014E (pt) 1997-10-17 2010-07-05 Genentech Inc Homëlogos de toll humana
WO1999046368A2 (en) 1998-03-13 1999-09-16 Biomarin Pharmaceuticals Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment
EP1062319A4 (de) 1998-03-13 2003-04-23 Human Genome Sciences Inc Vaskulärer , endothelspezifischer wachstumsfaktor
US6171575B1 (en) 1998-04-06 2001-01-09 Shinichi Okuyama Method of radioisotopic assessment of the integrity and function of the nose-brain barrier
JP2003527822A (ja) 1998-08-27 2003-09-24 マサチューセッツ インスティテュート オブ テクノロジー ヘパリナーゼｉおよびｉｉ由来の合理的に設計されたヘパリナーゼ
ES2478257T3 (es) 1998-10-06 2014-07-21 Stryker Corporation Composición que comprende una proteína osteogénica seleccionada del grupo que consiste en OP-2, OP-3, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-9, BMP-10, BMP-11 , BMP-15, BMP-3B, DPP, Vg-1, Vgr-1, proteína 60A, GDF-1, GDF-2, GDF-3, GDF-6, GDF-7, GDF-8, GDF-9, GDF-10, y GDF-11 para su uso en la reparación de defectos del cartílago no articular
WO2000062067A1 (en) 1999-02-28 2000-10-19 Washington University Novel transduction molecules and methods for using same
JP2003500016A (ja) 1999-04-02 2003-01-07 イーライ・リリー・アンド・カンパニー ｈＯＢ−ＢＰ２ｈ組成物、方法およびその使用
SE9901428D0 (sv) 1999-04-21 1999-04-21 Karolinska Innovations Ab Amphibodies
MEP3208A (xx) 1999-06-08 2010-02-10 Regeneron Pharma Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama
WO2001039795A2 (en) 1999-12-02 2001-06-07 Ibex Technologies, Inc. Attenuation of fibroblast proliferation
ES2444710T3 (es) 2000-06-22 2014-02-26 Amgen, Inc. Uso de un anticuerpo específico para un polipéptido similar a IL-17
US20020142299A1 (en) 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
CA2438661C (en) 2001-02-15 2011-05-31 University Of Chicago Yeast screens for agents affecting protein folding
CA2367636C (en) 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
AU2002311535A1 (en) 2001-06-26 2003-01-08 Decode Genetics Ehf. Nucleic acids encoding protein kinases
ATE543509T1 (de) 2001-08-13 2012-02-15 Univ Florida Material und verfahren zur förderung der reparatur von nervengewebe
US20030049258A1 (en) 2001-09-11 2003-03-13 Martin Ungerer Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle
CA2461343A1 (en) 2001-10-09 2003-04-17 Immunex Corporation Mammalian c-type lectins
GB0205022D0 (en) * 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
US8183350B2 (en) 2002-05-04 2012-05-22 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
AU2003220115A1 (en) 2002-05-20 2003-12-12 Board Of Regents, The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
DE60334220D1 (de) 2002-06-03 2010-10-28 Massachusetts Inst Technology Rationell konstruierte, von chondroitinase b abgeleitete lyasen
US7163545B2 (en) 2002-07-29 2007-01-16 Mayo Foundation For Medical Education And Research Spinal cord surgical implant
JP4527950B2 (ja) 2002-08-09 2010-08-18 シスメックス株式会社 脂質測定試薬
US7074581B2 (en) 2002-08-09 2006-07-11 Sysmex Corporation Reagent for assaying lipid
CA2495121A1 (en) 2002-08-10 2004-02-19 Yale University Nogo receptor antagonists
AU2003265561A1 (en) 2002-08-15 2004-03-03 Acorda Therapeutics, Inc. Chimeric protein
JP2004113166A (ja) 2002-09-27 2004-04-15 Mitsui Chemicals Inc ハロペルオキシダ−ゼ活性の安定化方法
EP1631234B1 (de) 2003-05-16 2011-09-14 Acorda Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von zns-schäden
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
EP2460881B1 (de) 2003-05-16 2017-05-03 Acorda Therapeutics, Inc. Proteoglycan-abbauende Mutanten zur Behandlung des ZNS
AU2004247025B8 (en) 2003-05-16 2011-06-30 Acorda Therapeutics, Inc. Fusion proteins for the treatment of CNS
WO2005087920A2 (en) 2004-03-10 2005-09-22 Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
MXPA06013345A (es) 2004-05-18 2008-10-31 Acorda Therapeutics Inc Metodos para purificar condrointinasa y sus formulaciones estables.
WO2007038548A2 (en) 2005-09-26 2007-04-05 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
WO2008045970A2 (en) 2006-10-10 2008-04-17 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants

Also Published As

Publication number Publication date
ES2362648T3 (es) 2011-07-08
AU2003304173A8 (en) 2005-01-04
ATE500842T1 (de) 2011-03-15
US20120207732A1 (en) 2012-08-16
WO2004108069A2 (en) 2004-12-16
US20150023942A1 (en) 2015-01-22
US8785606B2 (en) 2014-07-22
AU2003304173A1 (en) 2005-01-04
US8183350B2 (en) 2012-05-22
EP1575548A4 (de) 2007-07-04
EP1575548B1 (de) 2011-03-09
US20160279210A1 (en) 2016-09-29
EP2301564A1 (de) 2011-03-30
EP1575548A2 (de) 2005-09-21
US20070274979A1 (en) 2007-11-29
US9956273B2 (en) 2018-05-01
WO2004108069A3 (en) 2006-12-14
US9468671B2 (en) 2016-10-18

Similar Documents

Publication Publication Date Title
DE60336341D1 (de) Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
DE60335244D1 (de) Behandlung von verletzungen des zentralen nervensystems
DE69910368D1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
DE60233805D1 (de) Zusammensetzungen und verfahren zur isolierung, vermehrung und differenzierung nicht-embryonale menschlicher stammzellen und deren verwendungen
DE60335743D1 (de) Verbindungen und verfahren zur erhöhung der neurogenese
DE602006010776D1 (de) Piperazinylalkylpyrazol-Derivate zur Verwendung als selektive Calciumkanalblocker des T-Typs und Verfahren zu ihrer Herstellung
ATE524067T1 (de) Zusammensetzungen und verfahren zur behandlung von zns-schäden
ES2193938T3 (es) Transplante de celulas hematopoyeticas.
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE516040T1 (de) Zusammensetzung und verwendung zur vorbeugung oder behandlung von stomatitis
NO20052153L (no) Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer.
ATE473277T1 (de) Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten
ATE370739T1 (de) Verwendung von hesperidin oder einem seiner derivate zur herstellung eines medikaments für die stimulierung der knochenbildung
IL176453A0 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
DE60018591D1 (de) Milchsäurebakterien zur behandlung und prophylaxe von giardiasis
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DE60039579D1 (de) Humane adulte astrozyten, sowie deren herstellung und verwendung
PT1255734E (pt) Derivados de isatina com actividade neurotrofica
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
DE60200160D1 (de) Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE276752T1 (de) Verwendung von niedermolekularen heparinen zur vorbeugung und behandlung von einem trauma des zentralnervensystems
DE602004016292D1 (de) Verwendung einer zusammensetzung mit vitamin k1-oxid oder einem derivat daraus zur behandlung und/oder vorbeugung von hautverletzungen bei säugern
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen